WASHINGTON, DC — More than 3,700 bottles of a prescription blood pressure medication have been recalled across the United States because the tablets may not dissolve properly, according to a Food and Drug Administration recall notice. The voluntary recall covers a generic combination medicine made by Macleods Pharma USA and distributed nationwide.
The affected drug contains the same three active ingredients as the brand-name medication Tribenzor: olmesartan medoxomil, amlodipine and hydrochlorothiazide. The FDA notice does not list any Tribenzor-branded product in the recall, only certain generic lots of the combination tablet.
Federal regulators classified the recall as Class II on Oct. 26. That designation means the product could cause temporary or medically reversible health problems, while the chance of serious harm is considered remote.
Which blood pressure tablets are included in the recall
The recall applies to tablets containing 40 mg of olmesartan medoxomil, 10 mg of amlodipine and 12.5 mg of hydrochlorothiazide. In all, 3,744 bottles are affected, according to the FDA notice.
Macleods Pharmaceuticals Ltd. manufactured the medication in Daman, India, for Macleods Pharma USA, which is based in Princeton, New Jersey. The product was then distributed nationwide in the United States.
That means patients could encounter the recalled medicine in pharmacies or household medicine cabinets in many parts of the country. The FDA notice focuses on the specific lots included in the action, so the bottle label and lot information matter when checking for exposure.
Why the FDA says the medication was pulled
The recall centers on a problem with how the tablets may behave after a patient takes them. If the pills do not dissolve properly, the dose may not be released as intended, which is why the FDA and the company moved to pull the affected lots.
Because the recall is classified as Class II, regulators consider the health risk to be limited. The agency says the issue may lead to temporary or medically reversible problems, rather than a high likelihood of severe injury.
Even with that classification, the problem is still important for people taking blood pressure medication. Blood pressure treatment often relies on consistent dosing, so any issue with tablet dissolution can be significant for patients and prescribers.
What patients should check on their prescription bottles
Patients are being told to examine their prescription bottle carefully and compare the medication name, manufacturer and lot number with the recalled product. Those details determine whether a bottle is part of the affected shipment.
If a bottle matches the recall, patients should not simply throw the medicine away or make a dosing change on their own. The FDA says people should speak with a doctor or pharmacist before stopping a prescribed blood pressure medication.
The agency also says patients can generally keep using medication involved in a Class II recall unless the company or the FDA gives different instructions. That guidance is meant to prevent unnecessary interruptions in treatment while the recall is being handled.
How doctors and patients can report problems to the FDA
Patients and health care professionals who notice side effects or medication-quality problems can report them through the FDA’s MedWatch Safety Information and Adverse Event Reporting Program. The agency also accepts reports by phone at 800-FDA-1088.
MedWatch is the FDA’s standard channel for tracking adverse events and quality complaints tied to drugs and other regulated products. Reports from patients and clinicians help the agency monitor whether a recall is producing real-world problems beyond the label notice.
That reporting step is especially important when a medicine is used to manage a chronic condition like high blood pressure. It gives regulators and manufacturers additional information while patients sort out whether their own supply is affected.
What the recall means for people taking combination blood pressure medicine
The medicine involved in the recall combines three drugs in one tablet, which is common in blood pressure treatment because it can simplify daily use. The recalled product includes olmesartan medoxomil, amlodipine and hydrochlorothiazide in a single dose.
For people who rely on that kind of combination therapy, any medication change should be handled carefully with a clinician or pharmacist. The FDA guidance makes clear that patients should confirm their bottle’s details before making decisions about use or replacement.
Because the medication was distributed nationwide, the recall could affect patients in many states rather than a single region. The key next step is checking the label against the recall information and following medical advice if there is a match.
Leave a Reply